Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
13 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Content**

**Notes:**

2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Osteoporosis - Overview 10
Osteoporosis - Therapeutics Development 11
Pipeline Overview 11
Pipeline by Companies 12
Pipeline by Universities/Institutes 18
Products under Development by Companies 19
Products under Development by Universities/Institutes 25
Osteoporosis - Therapeutics Assessment 27
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Osteoporosis - Companies Involved in Therapeutics Development 37
Addex Therapeutics Ltd 37
Alize Pharma SAS 37
Alvogen Korea Co Ltd 38
Amgen Inc 38
Acura Holdings Ltd 39
BiologicsMD Inc 39
Bone Biologics Corp 40
Bristol-Myers Squibb Company 40
Cellmid Ltd 41
ChoDang Pharm Co Ltd 41
Chugai Pharmaceutical Co Ltd 42
Corium International Inc 42
Critical Pharmaceuticals Ltd 43
Daiichi Sankyo Company Ltd 43
ElexoPharm GmbH 44
EndoCeutics Inc 44
Enteris Bio Ltd 45
Enteris BioPharma Inc 45
Enzo Biochem Inc 46
F. Hoffmann-La Roche Ltd 46
Gador SA 47
GL Pharm Tech Corp 47
Glide Pharmaceutical Technologies Ltd 48
Hanmi Pharmaceuticals Co Ltd 48
Haoma Medica Ltd 49
Immunovo BV 49
Immunwork Inc 50
Intas Pharmaceuticals Ltd 50
Ipsen SA 51
Kaken Pharmaceutical Co Ltd 51
Lead Discovery Center GmbH 52
Ligand Pharmaceuticals Inc 52
Lotus Pharmaceutical Co Ltd 53
Lupin Ltd 53
Merck & Co Inc 54
Mereo Biopharma Group Plc 54
NIBEC 55
Omeros Corp 55
Oncobiologics Inc 56
Osteologix Holdings Plc 56
Paras Biopharmaceuticals Finland Oy 57
Pfenex Inc 57
PhytoHealth Corp 58
R Pharm 58
Ribomic Inc 59
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 59
Shin Poong PharmCo Ltd 60
Sinil Pharmaceutical Co Ltd 60
Stelis Biopharma Pvt Ltd 61
Sumitomo Dainippon Pharma Co Ltd 61
Terpenoid Therapeutics Inc 62
TSH Biopharm Corporation Ltd 62
Uni-Bio Science Group Ltd 63
Viking Therapeutics Inc 63
Wroclawskie Centrum Badan EIT+ Sp z oo 64
Yooyoung Pharm Co Ltd 64
Zydus Cadila Healthcare Ltd 65
Osteoporosis - Drug Profiles 66
(acolbifene hydrochloride + prasterone) - Drug Profile 66
(cholecalciferol + raloxifene) - Drug Profile 67
(cholecalciferol + risedronate sodium) - Drug Profile 68
2-AMD - Drug Profile 69
3D-QM - Drug Profile 70
3D-QMS - Drug Profile 71
abaloparatide - Drug Profile 72
ADX-68693 - Drug Profile 80
KN-012 - Drug Profile 129
lasofoxifene tartrate - Drug Profile 130
MAb-4 - Drug Profile 133
MDY-1001 - Drug Profile 134
Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile 135
Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis - Drug Profile 136
NBS-101 - Drug Profile 137
NEP-28 - Drug Profile 138
OGX-528 - Drug Profile 139
OXY-133 - Drug Profile 140
OXY-149 - Drug Profile 141
OXY-153 - Drug Profile 143
PF-708 - Drug Profile 144
PHN-031 - Drug Profile 145
Protein to Antagonize PPAR Gamma-2 for Rheumatoid Arthritis, Obesity and Osteoporosis - Drug Profile 146
Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile 147
R-Spondin 1 - Drug Profile 148
RBM-007 - Drug Profile 149
Recombinant Peptide to Agonize PTH1R for Osteoporosis - Drug Profile 150
Recombinant Protein 1 for Osteoporosis and Rheumatoid Arthritis - Drug Profile 151
Recombinant Protein 2 for Osteoporosis and Rheumatoid Arthritis - Drug Profile 152
Recombinant Protein 3 for Osteoporosis and Rheumatoid Arthritis - Drug Profile 153
Recombinant Protein for Bone Disorders and Osteoporosis - Drug Profile 154
Recombinant Protein for Osteoporosis and Osteoarthritis - Drug Profile 155
Recombinant Protein for Osteoporosis and Rheumatoid Arthritis - Drug Profile 156
Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile 157
Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile 158
romosozumab - Drug Profile 159
RPH-203 - Drug Profile 165
S-0071500 - Drug Profile 166
S-008399 - Drug Profile 167
S-101479 - Drug Profile 168
SI-000513 - Drug Profile 169
Small Molecule for Oncology, Psoriasis and Osteoporosis - Drug Profile 170
Small Molecule for Osteoporosis - Drug Profile 171
Small Molecule to Activate sGC for Osteoporosis - Drug Profile 172
Small Molecule to Agonize Androgen Receptor for Osteoporosis - Drug Profile 173
Small Molecule to Agonize EP4 Receptor for Osteoporosis - Drug Profile 174
Small Molecule to Agonize LRP for Osteoporosis - Drug Profile 175
Small Molecule to Agonize PTH-1R for Osteoporosis - Drug Profile 176
Small Molecule to Antagonize OGR1 for Asthma, Bone Diseases, Oncology and Osteoporosis - Drug Profile 177
Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis - Drug Profile 178
Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis - Drug Profile 179
Small Molecule to Target LGR4 for Oncology and Osteoporosis - Drug Profile 180
Small Molecule to Target Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis - Drug Profile 181
Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 182
Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 183
Small Molecules for Osteopenia and Osteoporosis - Drug Profile 184
Small Molecules for Osteoporosis - Drug Profile 185
Small Molecules for Osteoporosis - Drug Profile 186
Small Molecules to Antagonize Calcium-Sensing Receptor for Osteoporosis - Drug Profile 188
Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis - Drug Profile 189
Small Molecules to Inhibit GGDPs for Bone Metastasis and Oncology - Drug Profile 190
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 191
Small Molecules to Inhibit Sclerostin for Osteoporosis - Drug Profile 192
Small Molecules to Target Estrogen Receptor for Breast Cancer and Osteoporosis - Drug Profile 193
Sodium Quinate - Drug Profile 194
SP-35454 - Drug Profile 195
SR-10171 - Drug Profile 196
SR-2595 - Drug Profile 197
Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile 198
Synthetic Peptide for Osteoporosis - Drug Profile 199
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 200
Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 201
TE-3110 - Drug Profile 202
TE-3236 - Drug Profile 203
teriparatide - Drug Profile 204
teriparatide - Drug Profile 205
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Osteoporosis - Pipeline by Addex Therapeutics Ltd, H1 2017
Osteoporosis - Pipeline by Alize Pharma SAS, H1 2017
Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H1 2017
Osteoporosis - Pipeline by Amgen Inc, H1 2017
Osteoporosis - Pipeline by Amura Holdings Ltd, H1 2017
Osteoporosis - Pipeline by BiologicsMD Inc, H1 2017
Osteoporosis - Pipeline by Bone Biologics Corp, H1 2017
Osteoporosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
Osteoporosis - Pipeline by Cellmid Ltd, H1 2017
Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2017
Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Osteoporosis - Pipeline by Corium International Inc, H1 2017
Osteoporosis - Pipeline by Critical Pharmaceuticals Ltd, H1 2017
Osteoporosis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2017
Osteoporosis - Pipeline by EndoCeutics Inc, H1 2017
Osteoporosis - Pipeline by Entera Bio Ltd, H1 2017
Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2017
Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2017
Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Osteoporosis - Pipeline by Gador SA, H1 2017
Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2017
Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2017
Osteoporosis - Pipeline by Immunovo BV, H1 2017
Osteoporosis - Pipeline by Immunwork Inc, H1 2017
Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
Osteoporosis - Pipeline by Ipsen SA, H1 2017
Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017
Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2017
Osteoporosis - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
Osteoporosis - Pipeline by Lupin Ltd, H1 2017
Osteoporosis - Pipeline by Merck & Co Inc, H1 2017
Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H1 2017
Osteoporosis - Pipeline by NIBEC, H1 2017
Osteoporosis - Pipeline by Omeros Corp, H1 2017
Osteoporosis - Pipeline by Oncobiologics Inc, H1 2017
Osteoporosis - Pipeline by Osteologix Holdings Plc, H1 2017
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
Osteoporosis - Pipeline by Pfenex Inc, H1 2017
Osteoporosis - Pipeline by PhytoHealth Corp, H1 2017
Osteoporosis - Pipeline by R Pharm, H1 2017
Osteoporosis - Pipeline by Ribomic Inc, H1 2017
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H1 2017
Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017
Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2017
Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2017
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2017
Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2017
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2017
Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
Osteoporosis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
List of Figures
- Number of Products under Development for Osteoporosis, H1 2017
- Number of Products under Development by Companies, H1 2017
- Number of Products under Development by Universities/Institutes, H1 2017
- Number of Products by Top 10 Targets, H1 2017
- Number of Products by Stage and Top 10 Targets, H1 2017
- Number of Products by Top 10 Mechanism of Actions, H1 2017
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
- Number of Products by Top 10 Routes of Administration, H1 2017
- Number of Products by Stage and Top 10 Routes of Administration, H1 2017
- Number of Products by Top 10 Molecule Types, H1 2017
- Number of Products by Stage and Top 10 Molecule Types, H1 2017

Buy This Report

Single License : $2000

Request sample of this report
Check discount this report

Go For Report

https://www.marketresearchreports.biz/reports/1070423/osteoporosis-pipeline-review-h1-2017-market-research-reports

Office: United States
State Tower, 90 State Street, Suite 700, Albany, NY 12207, United States
<table>
<thead>
<tr>
<th>Toll Free: 866-997-4948 (USA-Canada)</th>
<th>Tel: +1-518-621-2074</th>
</tr>
</thead>
<tbody>
<tr>
<td>E: <a href="mailto:sales@marketresearchreports.biz">sales@marketresearchreports.biz</a></td>
<td></td>
</tr>
</tbody>
</table>